Sarah Whittle, Rajkumar Venkatramani, Anton Schönstein, Svetlana D Pack, Rita Alaggio, Christian Vokuhl, Erin R Rudzinski, Anna-Lena Wulf, Angelica Zin, Juliana R Gruver, Michael A Arnold, Johannes H M Merks, Simone Hettmer, Ewa Koscielniak, Frederic G Barr, Douglas S Hawkins, Gianni Bisogno, Monika Sparber-Sauer
BACKGROUND: Spindle cell rhabdomyosarcoma (RMS) is a rare variant of RMS accounting for up to 10% of cases in infants. In older children and adults, spindle cell RMS is associated with MYOD1 mutations and a poor prognosis. In infants, it is associated with recurring fusions involving NCOA2 and VGLL2. Reports in the literature suggest a favorable prognosis for this subset, however, little is known about treatment and outcome data of infants with spindle cell RMS. METHODS: Characteristics, treatment, and outcome of an international cohort of 40 patients aged ≤ 12 months with spindle cell RMS treated from 1997 to 2018 were evaluated...
June 2022: European Journal of Cancer